

3-Bromo-8-methylimidazo[1,2-a]pyridine-6-carboxylic acid (C₉H₇BrN₂O₂) is a highly functionalised, bicyclic heterocyclic building block extensively utilised as an advanced intermediate in discovery-phase medicinal chemistry, high-throughput screening campaigns, and commercial API synthesis. Due to its rigid, electron-rich core and orthogonal halogen/carboxylic acid handle configuration-serves-critical candidate framework across multiple innovative drug development sectors Synthetic viability and downstream efficiency of our 3-Bromo-8-methylimidazo[1,2-a]pyridine-6-carboxylic acid rely on rigorous regioselective control during ring closure and subsequent halogenation. Imidazo[1,2-alpyridine nucleus naturally features competitive nucleophilic and electrophilic reaction centres. If the electronic properties of the starting aminopyridine or alpha-halocarbonyl precursors are unevenly managed, side reactions like self-condensation, decarboxylation, or multi-halogenation can occur. These impurities are highly structural mimics that easily carry forward, permanently poisoning precious organometallic catalysts during late-stage cross-coupling phases. Our advanced processing infrastructure eliminates open-market structural variance through strict control of reaction parameters. Our multi-step synthesis path utilises ultra-pure aminopyridine starting materials paired with stabilised acetal keys to guarantee a completely regioselective cyclisation loop. Final electrophilic bromination is tamely managed using electronic stabilisation additives to enforce highly targeted monobromination at the C-3 position while leaving the aromatic methyl group untouched. The resulting product is processed through a targeted chemical wash to remove raw succinimide complexes, delivering an exceptionally pure crystalline intermediate with an ultra-low trace-ash baseline. This level of purity ensures predictable, high-yield results for discovery chemists and scale-up engineers alike. We are a premier 3-Bromo-8-methylimidazo[1,2-a]pyridine-6-carboxylic acid supplier for high-purity 3-Bromo-8-methylimidazo[1,2-a]pyridine-6-carboxylic acid, ensuring consistent melting points and precise assay values. We deliver a comprehensive selection of 3-Bromo-8-methylimidazo[1,2-a]pyridine-6-carboxylic acid grades with full analytical documentation, including batch-specific (HPLC) purity verification profiles and supporting quality assurance data 3-Bromo-8-methylimidazo|1,2-aJpyridine-6-carboxylic acid COA and TDS. We ensure secure supply chains from pilot-lot evaluations to multi-container commercial campaigns worldwide with reliable lead time and global supply capabilities and logistics coordination in over 17+ countries.
![3-Bromo-8-methylimidazo[1,2-a] pyridine-6-carboxylic acid](/_next/image?url=https%3A%2F%2Fcdn.scimplify.com%2Fproducts%2Fimages%2F6a4dfeaf3f77e71fa4cd800c%2F1c4dd82a-667d-4a18-b3b3-a0acc88c780e.png&w=3840&q=75)
![3-Bromo-8-methylimidazo[1,2-a] pyridine-6-carboxylic acid](/_next/image?url=https%3A%2F%2Fcdn.scimplify.com%2Fproducts%2Fimages%2F6a4dfeaf3f77e71fa4cd800c%2F1c4dd82a-667d-4a18-b3b3-a0acc88c780e.png&w=3840&q=75)
3-Bromo-8-methylimidazo[1,2-a]pyridine-6-carboxylic acid (C₉H₇BrN₂O₂) is a highly functionalised, bicyclic heterocyclic building block extensively utilised as an advanced intermediate in discovery-phase medicinal chemistry, high-throughput screening campaigns, and commercial API synthesis. Due to its rigid, electron-rich core and orthogonal halogen/carboxylic acid handle configuration-serves-critical candidate framework across multiple innovative drug development sectors Synthetic viability and downstream efficiency of our 3-Bromo-8-methylimidazo[1,2-a]pyridine-6-carboxylic acid rely on rigorous regioselective control during ring closure and subsequent halogenation. Imidazo[1,2-alpyridine n...
Pharmaceutical
Pharmaceutical Actives & Precursors
Intermediates & Precursors
.7767eb0f.png)

Chemical Properties & Specifications
High-throughput medicinal chemistry screening, library synthesis, and clinical trial R&D
Commercial-scale active pharmaceutical ingredient (API) synthesis and regulated scale-up campaigns.
Foundational core structural pharmacophore for synthesising selective tyrosine kinase inhibitors (TKIs) and mitogen-activated protein kinase (MAPK) pathway modulators
Key scaffold in constructing functionalised nitrogen-bridgehead systems engineered to combat multi-drug-resistant (MDR) bacterial strains and viral replication assemblies
Integrated by global biotechnology entities into DNA-damage response (DDR) inhibitor designs and enzyme-targeted cell signaling inhibitors
Highly reactive, bifunctional connector matrix for building sophisticated macrocycles and specialised biochemical screening probes
This intermediate is primarily destined for palladium-catalyzed cross-coupling reactions via its C - 3 bromine handle. If trace unreacted input blocks, isomeric impurities, or residual salts remain in the crystal matrix, they function as powerful catalyst poisons. These contaminants form stable, unreactive complexes with expensive palladium phosphine ligands, causing reaction stagnation and high catalyst overhead. Our R&D Ultra Grade ensures an HPLC purity of ≥ 98.5% with single impurities restricted to ≤ 0.20%, enabling flawless organometallic catalysis. Due to the high-precision crystalline separations required, our standard spot-production lead time for technical commercial campaigns is 8 to 10 weeks.
Advanced heterocyclic intermediates require comprehensive regulatory data sheets to avoid lengthy border inspections and customs holds. All export campaigns of our imidazopyridine derivative are fully accompanied by an extensive, auditable documentation trail. This includes a batch-specific Certificate of Analysis COA, high-resolution HPLC purity profiles, GHS-compliant SDS, and complete TDS. Our products conform to the regulatory compliance frameworks of more than 17 countries, allowing seamless integration into global pharmaceutical supply chains without customs friction.
Category : Pharmaceutical Actives & Precursors
Sub-Category : Active Pharmaceutical Ingredients (APIs)
Description : Calcium acetate monohydrate (CAS No: 5743-26-0) occupies a critical position in the global specialit...
Category : Pharmaceutical Actives & Precursors
Sub-Category : Intermediates & Precursors
Description : P-Nitrobenzoyl Chloride (CAS 122-04-3) is a critical building block in the API intermediates market,...